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Detection of circulating tumour cell clusters in human
glioblastoma
Ilona Krol1, Francesc Castro-Giner1,2, Martina Maurer3, Soﬁa Gkountela1, Barbara Maria Szczerba1, Ramona Scherrer1,
Niamh Coleman 4, Suzanne Carreira4, Felix Bachmann3, Stephanie Anderson3, Marc Engelhardt3, Heidi Lane3,
Thomas Ronald Jeffry Evans5, Ruth Plummer6, Rebecca Kristeleit7, Juanita Lopez4 and Nicola Aceto1
Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating
tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular CTC clusters are generated in this
disease and whether they can bypass the physical hurdle of the blood–brain barrier. Here, we assessed CTC presence and
composition at multiple time points in 13 patients with progressing GBM during an open-label phase 1/2a study with the
microtubule inhibitor BAL101553. We observe CTC clusters ranging from 2 to 23 cells and present at multiple sampling time points
in a GBM patient with pleomorphism and extensive necrosis, throughout disease progression. Exome sequencing of GBM CTC
clusters highlights variants in 58 cancer-associated genes including ATM, PMS2, POLE, APC, XPO1, TFRC, JAK2, ERBB4 and ALK.
Together, our ﬁndings represent the ﬁrst evidence of the presence of CTC clusters in GBM.
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INTRODUCTION
Human glioblastoma (GBM) is the most common and aggressive
primary brain cancer in adults.1 Yet, despite its characteristic
invasive features and hypervascularity determined by angiogenic
recruitment, only 0.4–2% of GBM patients develop metastasis
outside of the central nervous system.2 The rarity of these
metastatic events has been attributed to the short-term survival of
patients after initial GBM diagnosis, leaving insufﬁcient time for
establishment of extracranial lesions, as well as to the presence of
the blood–brain barrier, which physically separates the brain from
the rest of the body.3 Circulating tumour cells (CTCs) are cancer
cells that detach from a primary tumour lesion or a metastatic
deposit and enter the bloodstream.4 Although individual CTCs
have been sporadically observed in GBM,5–8 it is unclear whether
multicellular CTC clusters9 are generated and are able to pass
through the blood-brain barrier in patients with GBM.
MATERIALS AND METHODS
Patient selection and recruitment
Patients were participants in the GBM arm of the ongoing study
‘An open-label Phase 1/2a study of oral BAL101553 in adult
patients with advanced solid tumours and in adult patients with
recurrent or progressive glioblastoma or high-grade glioma’
(NCT02490800). The main eligibility criteria for GBM patients in
the study are measurable disease, deﬁned by contrast-enhancing
magnetic resonance imaging (MRI), and an Eastern Cooperative
Oncology Group performance status of ≤ 2. The study was
conducted in accordance with the Declaration of Helsinki (2000)
and the International Conference on Harmonisation Guidelines for
Good Clinical Practice. The study was approved by each study
centre’s Research Ethics Committee and all patients provided
written informed consent before enrolment.
Mouse experiments
All mouse experiments were carried out according to institutional
and cantonal guidelines (approved mouse protocol 2781, cantonal
veterinary ofﬁce of Basel-City). To measure GBM CTC intravascular
aggregation, Nod Scid Gamma mice (The Jackson Laboratory, Bar
Harbor, Maine, USA) were injected through the tail vein with a 1:1
mixture of T98G-GFP and T98G-RFP GBM cells, and upon injection,
whole blood was withdrawn through a heart puncture and
processed with the Parsortix device to characterise CTC
composition.
GBM CTC enumeration
To test the GBM cell capture rate, healthy donor blood samples
were drawn in three different collection tubes: CF DNA blood
collection tube (BCT) (Streck, 218997), CellSave (CellSearch,
7900005) and Cyto-Chex BCT (Streck, 213386). The blood was
then spiked with 300 human GBM T98G cells (Sigma, 92090213,
CRL-1690) stably expressing green ﬂuorescent protein (GFP).
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T98G-GFP cells were generated by transduction with UBC-GFP-
T2A-Luc-expressing lentiviral particles (SBI, BLIV201PA-1-SBI). After
incubation at room temperature (RT) for 24, 48, 72, and 96 h,
samples were processed with the Parsortix microﬂuidic system for
CTC enrichment. After wash with phosphate-buffered saline (PBS),
Parsortix cassettes were scanned and GFP-positive cells were
counted using Leica DMI 6000 microscope. To test artiﬁcial
clustering of CTCs within the Parsortix cassettes, we spiked
100 single T98G-GFP and 100 single T98G-RFP into CF DNA BCT
(Streck, 218997) tubes containing healthy donor blood. Upon
processing through the Parsortix microﬂuidic system, we enum-
erated the ratios between single colour CTC and multicolour CTCs
as a direct measure of on-chip CTC aggregation.
Tumour volume measurements
The enhancing tumour volume (cm3) and the corresponding FLAIR
signal abnormality volume (cm3) in patients were calculated with
Horos, an open source medical image viewer (LGPL license at
Horosproject.org, sponsored by Nimble Co LLC d/b/a Purview in
Annapolis, MD US).
CTC capture from GBM patients
Patients’ blood samples were collected into the Streck CF DNA
BCTs (Streck, 218997) and directly shipped at controlled tempera-
ture (RT). Samples were then loaded into the Parsortix microﬂuidic
device within 24–48 h after collection from the patient and
immediately processed for CTC enrichment. CTCs were
then enriched from blood samples at 16 °C in disposable Parsortix
cassettes (GEN3D6.5, ANGLE) according to the manufacturer’s
instruction and with a customised processing ﬂow rate of 0.33mm/
s in the narrowest cassette gap (6.5 μm). After separation, GBM
cells within cassettes were washed with PBS and further processed
for immunostaining with antibodies against EGFR (Cell Signaling),
Ki67 (Sigma), EB1 (kindly provided by Basilea Pharmaceutica), and
CD45 (Thermo Fischer). As an additional conﬁrmation, putative
CTCs as well as a matched primary tumour biopsy of patient 4 were
stained with antibodies against SOX2 (Cell Signaling).
Micromanipulation and exome sequencing
CTCs were released from the Parsortix cassette into ultra-low
attachments culture plates. Cells were picked using micromani-
pulation (CellCelector, ALS) and transferred to RTL Plus buffer
(Qiagen) within individual microcentrifuge tubes. Next, genomic
DNA was ampliﬁed using the MDA method (GenomiPhi V3, GE
Healthcare) and subject to Illumina library preparation with
SureSelect XT Human All Exon V6+ Cosmic kit (Agilent Technol-
ogies). Sequencing was performed on HiSeq 2500 platform
(Illumina) with 101 bp paired-end mode. For primary tumour
sequencing, three 10 μm-thick parafﬁn sections from a primary
tumour biospy were digested in DNA digestion buffer (50 mM Tris-
HCl pH 8.5, 1 mM EDTA pH 8.0 and 0.5% Tween with addition of
Proteinase K) in an eppendorf tube at 56 °C for 1 h, followed by 1 h
incubation at 90 °C and 5min at 95 °C. Samples were then kept on
ice until RNase A treatment was performed (30minutes at 37 °C).
Next, DNA was precipitated using 7.5 M ammonium acetate and
100% isopropanol. After washing with 70% ethanol, the DNA
pellet was air dried and then resuspended in standard Tris-
containing buffer. Sequencing was performed on HiSeq 2500
platform (Illumina).
Exome-sequencing data analysis and mutation calling
After quality control performed with FastQC (v0.11.4), reads were
mapped to the GRCh38 human reference genome using BWA-
mem (v0.7.13) algorithm and sorted using Samtools (v1.3.1). Reads
were then processed using Picard MarkDuplicates (v2.9.0) to
remove duplicated reads and realigned using GATK IndelRealign-
ment (v3.7.0) to improve alignment accuracy around indels. We
used the interactive platform Ginkgo (http://qb.cshl.edu/ginkgo) to
compute and plot the copy number proﬁles of single-cells. Input
bed ﬁles were generated from BAM alignments using BEDTools
(v2.26.0) and genomic coordinates were converted from GRCh38
to GRCh37 UCSC liftOver tool. Ginkgo was run with a using variable
bin size of 500 kb simulated with 101 bp with BWA and normalised
read counts for cell segmentation. Variants were identiﬁed using
Monovar (20160514 update) for low-input DNA samples and
bcftools (version 1.6) for primary GBM of patient 4. Resulting
variants were annotated using snpEff (v4.3p) with Ensembl
GRCh38.86 gene models. Putative somatic SNV were deﬁned as
variants not present in the white blood cell (WBC) pool and whose
frequency in the dbSNP (build 150) was < 1%. In addition, a more
stringent set of somatic single nucleotide variants (SNVs) was
obtained by ﬁltering out loci that were covered with < 5 reads in
the WBC pool. Candidate somatic driver variants were deﬁned as
variants annotated with high or moderate impact according to
snpEff, previously reported in the COSMIC (version 81) or located in
recurrently mutated genes in gliobastoma according to the CGC
database (version 81). Data analysis was conducted in R (version
3.4.0). Data visualisation was performed with the R package UpSetR
and the Bioconductor package GenVisR.
RESULTS
CTC detection strategy in GBM patients
Patients selected for CTCs investigation were part of an ongoing
open-label Phase 1/2a study arm of oral BAL101553, a water-
soluble microtubule inhibitor, in adult individuals with recurrent or
progressive GBM or high-grade glioma. Upon informed consent,
serial peripheral blood samples were drawn in Streck tubes from
13 GBM patients at time points related to BAL101553 administra-
tion, including (1) within the 2 weeks before the ﬁrst study-drug
treatment; (2) pre-dose, (3) 2 h post-dose and (4) 24 h post-dose
on Cycle 1 Day 1; and pre-dose on (5) Cycle 1 Day 8, (6) Cycle 1
Day 22 and (7) Cycle 2 Day 22 (Fig. 1a). Blood samples were then
processed within 48 h for CTC enumeration and characterisation.
To investigate CTC number and composition in GBM patients, we
made use of a commercially available CTC detection method, the
Parsortix microﬂuidic technology, customised to detect both
single and clustered GBM CTCs in an antigen-independent
manner and at > 98% capture efﬁciency, up to 48 h upon
ﬁxation in Streck CF DNA tubes (see methods and Supplementary
Fig. 1a-c), and without the occurrence of artiﬁcial CTC aggregates
during processing (Supplementary Fig. 1d,e). Brieﬂy, blood
samples were run through the Parsortix microﬂuidic cassette at
a ﬂow rate corresponding to 0.33 ml/s in the narrowest channel
section, ensuring label-free physical capture of CTCs and their
separation from blood components (Fig. 1b). Upon capture, CTCs
were stained with a dedicated GBM CTC antibody cocktail
containing antibodies against EGFR, Ki67 and the microtubule-
associated protein EB1, as well as against the WBC marker CD45 to
exclude leukocyte contamination (Supplementary Fig. 2). Putative
GBM CTCs were scored positive when corresponding to at least
one of these criteria: (1) cell diameter of at least 9 μm and negative
CD45 staining, and/or (2) positive EGFR, Ki67 or EB1 staining and
negative CD45 staining. With these parameters, and using healthy
blood donors (n= 3) to deﬁne a false-positive detection threshold,
we found that 7/13 patients were positive for at least 3 putative
CTCs per 10 ml of blood during at least 1 time point (Fig. 1c).
Importantly, radiological imaging determined that none of the 13
patients enroled in the study developed extracranial metastasis
(data not shown), and no association was observed between
functional MRI volume and the presence of CTCs, most likely due
to the small patient cohort (n= 13) (Supplementary Fig. 3).
Detection of GBM CTC clusters
Among patients that resulted positive for putative GBM CTCs, we
focused on a 43-year-old female patient (4), featuring the highest
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number of CTC events in the peripheral circulation. The patient
had a ﬁrst surgical resection of a right parietal GBM, which showed
a high-grade astrocytic tumour with pleomorphism, mitoses,
extensive necrosis and prominent vascular proliferation. Following
surgery, the patient underwent chemoradiotherapy comprising
standard radiation plus concomitant and subsequent adjuvant
temozolomide. Imaging at the end of adjuvant treatment
suggested progressive disease, requiring a second surgical
resection followed by procarbazine/lomustine/vincristine (PCV)
chemotherapy and re-irradiation. Further disease progression was
noted and subsequently the patient was enroled onto the
BAL101553 clinical trial (Supplementary Fig. 4a). MRI of the brain
before commencing BAL101553 therapy and CTC enumeration
showed enhancing tumour areas in the posterior aspect of the
right parietal lobe, inﬁltrating the corpus callosum and extending
periventricular along the occipital horn of the right lateral ventricle
and inferiorly into the temporal lobe (Supplementary Fig. 4b).
There were no other abnormalities seen on baseline whole-body
radiological imaging (data not shown). CTC analysis revealed the
presence of clusters of putative CTCs in the blood of this patient,
ranging from 2 to 23 cells and expressing various combinations of
EGFR, Ki67 and EB1 markers, yet negative for CD45 (Fig. 1d and
Supplementary Fig. 4c). As a further validation step, putative GBM
CTC clusters, as well as a biopsy from the primary GBM of patient 4
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Fig. 1 Identiﬁcation of GBM CTC clusters. a Schematic overview of the CTC isolation strategy (red) in GBM patients undergoing treatment with
BAL101553. Each patient underwent several blood draws: one or two blood draws before BAL101553 treatment (pre-tx), four during the ﬁrst
BAL101553 cycle and one during the second BAL101553 cycle. b Schematic representation of our CTC enrichment strategy with the Parsortix
microﬂuidic device. CTCs are captured with a size-based antigen-agnostic approach, while red and white blood cells ﬂow through the device.
c Plot showing the mean number of CTCs found at each sampling time point (pre-treatment: pre-TX; cycle 1 and cycle 2) in 13 GBM patients.
Healthy donors samples (HD; n= 3) provide a false-positive threshold of two putative CTCs per 10 ml blood. Patients with > 2 putative CTCs
per 10 ml of blood during at least one time point are shown in red. d Plot showing the number of cells per each GBM CTC cluster isolated from
patient 4. e Plot showing the number of GBM CTC clusters per 10ml of blood identiﬁed in patient 4 during each blood draw, both pre-
treatment (pre-TX) and post-treatment (cycle 1 and cycle 2) with BAL101553. P= 0.462 by Student’s t-Test. NS: not signiﬁcant. f Schematic
representation of the CTC isolation strategy by ﬂow reversion and picking with a micromanipulator. g Putative somatic mutations in
glioblastoma candidate driver genes found in GBM CTC clusters. The central panel shows the mutated genes coloured by the predicted
consequence of the mutations. The top panel shows the number of mutations per sample and the left panel shows the percentage of samples
that have a mutation in each represented gene
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were stained with the GBM marker SOX2, revealing SOX2-positive
cells in both specimens (Supplementary Fig. 4d, e). Similar to
breast cancer,9 we also conﬁrmed that GBM CTCs are not able to
form intravascular aggregates upon injection in the venous
circulation of mice (Supplementary Fig. 5a,b), indicating that the
putative CTC clusters observed in patient 4 are likely to be direct
derivatives of the primary GBM tumour. As a relatively stable
number of putative CTC clusters were observed in the samples
taken prior to and after initiation of BAL101553 therapy, it does
not appear as though the treatment itself impacted on CTC
clusters release at this dose level (Fig. 1e).
Exome sequencing of GBM CTC clusters
To assess whether the cell clusters isolated from the patient of
interest were bona ﬁde GBM cells, we released them in solution
from the Parsortix device and, with a semi-automatic micro-
manipulator, we deposited each cluster individually into lysis
buffer (Fig. 1f), followed by DNA ampliﬁcation and library
preparation for exome sequencing. Six samples were success-
fully sequenced, including one WBC pool as germline control
and ﬁve putative GBM CTC clusters. We obtained an average of
41 million reads per sample, corresponding to a median
coverage depth of 32.6 × and an average breadth of 18.7%, in
range with typical performance of single-cell-resolution exome
sequencing of ﬁxed cells10 (Supplementary Fig. 6a and Suppl.
Table 1). To address whether our putative GBM CTC clusters
were indeed of cancer origin, we adopted two parallel
approaches. First, we inferred DNA copy number variations
(CNVs) from exome-sequencing data in all our samples (see
Methods section). In general, while CNV assessment from single-
cell-resolution exome sequencing cannot precisely determine
CNV in exact regions due to the relative low coverage and
possible ampliﬁcation biases, we sought to use it to investigate
general aneuploidy trends across cells. We found that while
predicted ploidy for WBC control pool was 2, all putative GBM
CTC clusters displayed a predicted ploidy ranging from 2.2 to
4.1, suggesting a higher degree of genomic rearrangements
compared with the WBC control pool (Supplementary Fig. 6b).
Second, we identiﬁed variations at the nucleotide level in both
the WBC control pool as well as the putative GBM CTC clusters.
Genetic variations identiﬁed in both the putative CTC clusters
and the WBC control pool were considered likely to be part of
the patient’s germline variants and not included for further
analyses. We then interrogated speciﬁc GBM-associated genes
(see Methods section) and found among them a premature
STOP codon in ATM gene and missense variants in PMS2 and
POLE genes in GBM CTC clusters (Fig. 1g and Suppl. Table 2). Of
note, the region corresponding to the STOP codon in ATM gene
and the majority of the other variants were covered and found
to contain a wild-type sequence in the WBC pool control sample
(Suppl. Table 2). More generally, when interrogating the whole
exome of the putative GBM CTC clusters, we found that they
were carrying at total of 116 variants (possibly both driver and
passenger mutations) comprised in a total of 58 cancer-
associated genes (i.e., genes that were reported in the COSMIC
database and whose corresponding substitutions were leading
to either structural variants, premature STOP codon, or missense
variants) including APC, XPO1, TFRC, JAK2, BRCA2, ERBB4 and ALK,
in addition to the GBM-associated genes ATM, PMS2 and POLE
(Supplementary Fig. 6c and Suppl. Table 3). Further, despite the
notorious difﬁculties in capturing the entire mutational hetero-
geneity of an individual’s primary GBM with a single biopsy,11
we asked whether any of the mutations found at the level of
GBM CTC clusters were also detectable in the primary tumour.
Deep sequencing of a matched primary tumour biopsy of
patient #4 revealed that 16 out of 116 GBM CTC cluster
mutations were indeed also found in the primary tumour (Suppl.
Table 3), including mutations in POLE, BRCA2, ALK, and TFRC
(Suppl. Table 4). Importantly, several of these loci that contained
mutations both in the primary tumour and GBM CTC clusters
were covered and found to contain a wild-type sequence in the
WBC pool control sample (Suppl. Table 4), conclusively
demonstrating the GBM origin of the isolated CTC clusters.
Together, our results provide the ﬁrst evidence that GBM can
release clustered CTCs, characterised by a distinct mutational
proﬁle, which pass beyond the blood–brain barrier and reach the
peripheral circulation.
DISCUSSION
Although CTC clusters have been highlighted as highly-efﬁcient
metastatic precursors,9 they remain a poorly characterised feature
of the metastatic process, mainly due to their dilution factor in the
blood of patients and challenges to isolate them without
disrupting cell–cell interactions. As further confounding factors,
physiological features such as the localisation of the primary
tumour, circulation dynamics and entrapment in capillary beds
may strongly inﬂuence the number of detected CTC clusters in the
peripheral circulation of a given patient.
Our work provides the ﬁrst evidence that circulating glioblas-
toma clusters can overcome the blood–brain barrier and reach the
peripheral circulation. Yet, much remains to be understood in
regard to their biology and clinical relevance in this disease,
possibly using larger patient cohorts. In the future, it will be of
interest to explore the transcriptome of CTC clusters, to deﬁne
their genetic heterogeneity as compared with the primary tumour,
and to assess whether or not their presence in the peripheral
circulation correlates with GBM aggressiveness. We speculate that
since cancer cells are able to enter the blood circulation as clusters
in a non-epithelial cancer such as GBM, a limited cell–cell junction
repertoire12–14 may still be sufﬁcient to sustain CTC clustering and
ensure the preservation of multicellular structures beyond
vascular barriers. Further studies will be needed to test this
hypothesis and to identify key factors involved in CTC cluster
generation and passage through physical barriers. In addition, the
identiﬁcation of the essential cell–cell junction requirements to
maintain CTC clustering may lead to the development of novel
cluster-targeting agents.
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